MorphoSys

DGAP-News: MorphoSys Reports Second Quarter and First Half 2020 Results

Wednesday, August 5, 2020 - 10:27pm

Conference call and webcast (in English) to be held on August 6, 2020 at 2:00pm CEST (1:00pm BST/8:00am EDT)

Key Points: 
  • Conference call and webcast (in English) to be held on August 6, 2020 at 2:00pm CEST (1:00pm BST/8:00am EDT)
    MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) reports results for the second quarter and first half of 2020.
  • MorphoSys and Incyte are prepared for the successful commercial launch of Monjuvi(R) (tafasitamab-cxix), following its FDA approval on July 31, 2020.
  • Group revenues for the second quarter of 2020 amounted to 18.4 million (Q2 2019: 34.7 million).
  • MorphoSys continues its expansion of strategic presence of MorphoSys US Inc.
    MorphoSys Group Key Figures (IFRS, June 30, 2020)

Xencor Reports Second Quarter 2020 Financial Results

Tuesday, August 4, 2020 - 9:01pm

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended June 30, 2020 and provided a review of recent business and clinical highlights.
  • Total revenue for the second quarter ended June 30, 2020 was $13.1 million, compared to $19.5 million for the same period in 2019.
  • Research and development expenditures for the second quarter ended June 30, 2020 were $43.5 million, compared to $33.3 million for the same period in 2019.
  • ET (1:30 p.m. PT) to discuss these second quarter 2020 financial results and provide a corporate update.

Xencor Earns Milestone Payment from MorphoSys for FDA Approval of Monjuvi® (tafasitamab-cxix) in the United States

Saturday, August 1, 2020 - 3:49am

Xencor has earned a $25 million milestone payment from MorphoSys under the license agreement between the companies for Monjuvi in connection with the regulatory approval.

Key Points: 
  • Xencor has earned a $25 million milestone payment from MorphoSys under the license agreement between the companies for Monjuvi in connection with the regulatory approval.
  • Xencor licensed exclusive worldwide rights to develop and commercialize Monjuvi, product code MOR208 and previously XmAb5574, to MorphoSys in 2010.
  • "We are incredibly proud of Xencors discovery and early development of Monjuvi, an anti-CD19 antibody we engineered with our Cytotoxic XmAb Fc domain.
  • "Monjuvi follows Alexion's Ultomiris (ravulizumab-cwvz) as the second product incorporating XmAb technology to receive a marketing approval.

FDA Approves Monjuvi® (tafasitamab-cxix) in Combination With Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Saturday, August 1, 2020 - 12:51am

The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.

Key Points: 
  • The FDA decision represents the first approval of a second-line treatment for adult patients who progressed during or after first-line therapy.
  • The FDA approval of Monjuvi in combination with lenalidomide helps address an urgent unmet medical need for patients with relapsed or refractory DLBCL in the United States, said Herv Hoppenot, Chief Executive Officer, Incyte.
  • The FDA approval was based on data from the MorphoSys-sponsored Phase 2 L-MIND study, an open label, multicenter, single arm trial of Monjuvi in combination with lenalidomide as a treatment for adult patients with relapsed or refractory DLBCL.
  • The FDA previously granted Fast Track and Breakthrough Therapy Designation for the combination of Monjuvi and lenalidomide in relapsed or refractory DLBCL.

DGAP-News: Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

Thursday, July 30, 2020 - 9:02pm

Approximately two hours after the call, a slide-synchronized audio replay of the conference and a transcript of the prepared remarks will be available on www.morphosys.com.

Key Points: 
  • Approximately two hours after the call, a slide-synchronized audio replay of the conference and a transcript of the prepared remarks will be available on www.morphosys.com.
  • MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases.
  • Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.
  • Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements.

DGAP-News: MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

Tuesday, July 14, 2020 - 10:07pm

MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

Key Points: 
  • MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
    The issuer is solely responsible for the content of this announcement.
  • MorphoSys's Licensee Janssen Announces Approval of Tremfya(R) (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis
    MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) approval of Tremfya(R) (guselkumab) as a treatment for adult patients living with active psoriatic arthritis (PsA).
  • Dr. Malte Peters, Chief Research and Development Officer of MorphoSys, said: "Active psoriatic arthritis is a high burden for patients, causing limited mobility, pain and fatigue.
  • We are very pleased about the FDA approval for Tremfya(R), providing patients with a new treatment option for this debilitating indication."

AbCellera Files Patent Infringement Lawsuit Against Berkeley Lights, Inc.

Friday, July 10, 2020 - 7:01pm

AbCellera Biologics today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against Berkeley Lights, Inc. for patent infringement of U.S. Patent Nos.

Key Points: 
  • AbCellera Biologics today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against Berkeley Lights, Inc. for patent infringement of U.S. Patent Nos.
  • By its complaint, AbCellera is seeking a declaration by the Court that the defendant directly infringes, induces infringement, and contributes to the infringement of AbCellera's patents.
  • AbCellera is the market leader in the use of high-throughput microfluidics for single cell assays in nanoliter volumes with patent filing priority dates back to 2010.
  • AbCellera recently used its pioneering technology to discover the first human monoclonal antibody to be tested in a human patient, worldwide, against COVID-19.

Corbus Pharmaceuticals Appoints George Golumbeski, Ph.D., to Board of Directors

Wednesday, July 8, 2020 - 1:05pm

Dr. Golumbeski currently serves as a Director on the Boards of Enanta Pharmaceuticals, MorphoSys, Sage Therapeutics as well as several privately held companies.

Key Points: 
  • Dr. Golumbeski currently serves as a Director on the Boards of Enanta Pharmaceuticals, MorphoSys, Sage Therapeutics as well as several privately held companies.
  • Philosophically, I am highly aligned with Corbus focus on non-incremental scientific innovation directed at the highest degree of unmet medical needs.
  • I look forward to working with the Board and the Executive Team as Corbus approaches many strategic and corporate development milestones.
  • We are honored he has chosen to join us, said Alan Holmer, Chairman of Corbus Board of Directors.

DGAP-News: MorphoSys to Present at Upcoming Virtual Investor Conferences

Tuesday, June 2, 2020 - 10:07pm

In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval.

Key Points: 
  • In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval.
  • MorphoSys most advanced proprietary product candidate, tafasitamab (MOR208), is in late-stage clinical development for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).
  • Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.
  • More information at www.morphosys.com
    HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCER(R) are trademarks of the MorphoSys Group.

DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2020

Wednesday, May 27, 2020 - 7:03pm

Via a password-protected web service, registered shareholders could, among other things, visually and audibly follow the entire Annual General Meeting, exercise their voting rights and submit questions.

Key Points: 
  • Via a password-protected web service, registered shareholders could, among other things, visually and audibly follow the entire Annual General Meeting, exercise their voting rights and submit questions.
  • Effective April 11, 2020, Supervisory Board member Dr. Frank Morich resigned from the Supervisory Board of MorphoSys AG at his own request.
  • By resolution of today's Annual General Meeting, the size of the Supervisory Board was reduced to six members.
  • Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.